vf001-dp
Recombinant proteinexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02973893)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Insulin-like growth factor ISupplementation
IGF1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- vf001-dp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02973893 | Phase 2 | Nov 1, 2016 | Almac Clinical Services LLC, ARANZ Medical, Factor Therapeutics Ltd., Parexel, University of North Carolina at Chapel Hill |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Almac Clinical Services LLC | For profit | 1 | 0 | 1 | 2016 |
| ARANZ Medical | For profit | 1 | 0 | 1 | 2016 |
| Factor Therapeutics Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2016 |
5 organizations
Page 1 / 1